



## PharmAust Launches Interactive Investor Hub

**18 December 2023: PharmAust Limited (ASX: PAA)**, a clinical-stage biotechnology company, today announced the launch of its new Investor Hub. The interactive platform will allow existing and prospective shareholders to better engage with the company.

PharmAust's Investor Hub will host the latest company announcements, presentations, news and interviews. The interactive portal is also an opportunity for PharmAust's investor community to pose questions and comments directly to the company regarding news and updates on the portal.

PharmAust CEO, Dr Michael Thurn, said: "As PharmAust continues to see promising results in its clinical trials we feel it is important to give our investor community an easy way to keep up to date with company while maintaining an open channel of communication with the PharmAust team."

Interested stakeholders are encouraged to sign up for PharmAust's Investor Hub at: <https://investorhub.pharmaust.com/auth/signup>.

The Board authorises this announcement.

### Enquiries:

**Dr Michael Thurn**  
**Chief Executive Officer**  
[investorenquiries@pharmaust.com](mailto:investorenquiries@pharmaust.com)

**P +61 (8) 9202 6814**  
**F +61 (8) 9467 6111**  
[www.pharmaust.com](http://www.pharmaust.com)



### About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular "cleaning process", where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).

PAA's lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. Top-line results are expected to be announced in Q1 CY2024. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.